Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$16.3MCash on Hand
14.9mo Cash Runway
Follow INMB by emailGet an email when INMB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about INMB, unsubscribe in one click. Privacy
📣 What INMB Says Is Next
second quarter of 2027 · “Subject to feedback from that meeting, the Company plans to submit a Biologics License Application (BLA) in the second quarter of 2027, seeking traditional or accelerated approval, as appropriate.”
Company press release, Oct 21, 2026 · SEC filing
in February 2027 · “Following MHRA feedback on the final pre-MAA package, INmune Bio plans to finalize and submit a complete application in February 2027, replacing the sequential rolling submission previously planned to begin in late 2026.”
Company press release, Oct 21, 2026 · SEC filing
mid-2027 · “The company has updated its regulatory submission strategy, as faster-than-expected manufacturing progress supports a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review.”
Company press release, Oct 21, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 29, 2026 ·
Financing Offering 3,000,000 shares of common stock at $1.50 per share, plus concurrent private placement of warrants for up to 3,000,000 shares at $1.65 exercise price. Gross proceeds $4,500,000; placement agent fee 7.0%, proceeds before expenses $4,185,000. Form 424B5 · SEC filing
Oct 29, 2026 ·
Financing Entered a $4.5 million registered direct offering of 3,000,000 shares at $1.50 per share with a single investor, plus unregistered warrants for up to 3,000,000 shares at $1.65 exercisable from April 27, 2027. Placement agent fee is 7.0% of gross proceeds; closing expected October 29, 2026. Form 8-K · SEC filing · Press release
Oct 21, 2026 ·
Deal Entered a Master Services Agreement with Uniphar Durbin Ireland for international access and commercialization of Ebstrocel, starting with named-patient access in selected European and MENA markets. Submitted pre-MAA package for Ebstrocel (CORDStrom) to the UK MHRA. Form 8-K · SEC filing · Press release
Sep 14, 2026 ·
Leadership INmune Bio appointed R. Duane Clark II, General Manager of U.S. Rare Diseases at Sanofi, and James Sapirstein, a biopharma business development leader, as independent directors, expanding the Board to seven seats. Both receive 100,000-share option grants and a $50,000 annual cash retainer. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Sep 2025 · Phase 1/2 · Results Expected · Study of INKmune in Patients With mCRPC (CaRe Prostate) Registry primary completion date, not a results date
May 2025 · Phase 2 · Results Expected · A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation Registry primary completion date, not a results date
Jun 2021 · Phase 1 · Results Expected · A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
INMB holds $16.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.3M/quarter from operations,
an estimated runway of 14.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:55 · Elevated
Cash runway 15 months +18
ATM program on file since Dec 2025 +15
Shelf registration (S-3, May 2024) +10
Going-concern doubt in the latest 10-Q +15These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count +16% in a year +7
Raised after last reported balance sheet (Oct 2026) -10
Recent financing filings on SEC EDGAR:
Oct 29, 2026 · Registered direct / best-efforts offering · 424B5
Share count 30,959,079 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full INMB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INMB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.